Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
After publishing: 1 headline quietly rewritten, 1 description edited, 1 URL changed3 changes
- South China Morning Postseen 25 Aug, 14:23headline rewritten
As global drug giants grow cautious, can Chinese biotech keep cashing in on out-licensing?As drug giants grow cautious, can Chinese biotech firms still cash in on licensing deals? - prnewswire.comseen 25 Aug, 17:22URL changed
- South China Morning Postseen 27 Aug, 12:17description edited
what the description said, before and after
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer. The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharma industry increasingly looks to compete on the global stage. The Chinese trial tested ivonescimab and chemotherapy...Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase three trial for biliary tract cancer. The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharmaceutical industry increasingly looks to compete on the global stage. The Chinese trial tested ivonescimab and...
What it is about
Who published it, and when
+ 9 more outlets
How it spread - 62 original reports, 1 reprint
Wed, 5 August 2026
1 report- manilatimes.net20:30first to report
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ('Biofrontera' or the 'Company'), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.
Thu, 6 August 2026
2 reports- manilatimes.net11:40
Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS1 Parts I, II, and III, as well as a composite endpoint comprising 15 clinically relevant measures.
- manilatimes.net20:56
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (the 'FDA') has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive LP, cutaneous LP, and lichen planopilaris. Aclaris expects to initiate a phased...
Fri, 7 August 2026
1 report- yahoo.com11:05
BioVie used an endpoint called EPNIC-15, which is not well known and only appears to be referenced in papers by the company itself.
Fri, 14 August 2026
5 reports- manilatimes.net12:17
Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026.Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT. MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ('Annovis” or the 'Company”), a Phase 3 clinical-stage...
- manilatimes.net12:17
TUDRIQEV™in combination with nivolumab receives FDA accelerated approval and will launch within 60 days
- manilatimes.net12:17
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
- yahoo.com22:23Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron’s cemiplimab (Libtayo) in patients with solid tumors. BHV-1530’s novel topoisomerase I (TopoIx) payload generates immunogenic cell death and […]
- yahoo.com22:53
On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]
Mon, 17 August 2026
1 report- yahoo.com13:02
Fulcrum Therapeutics (NASDAQ:FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions. Alex S
Tue, 18 August 2026
5 reports- yahoo.com10:38
Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.
- prnewswire.com11:00
/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
- rttnews.com11:03
The following biotech stocks reached a 52-week high on August 17, 2026, driven by key catalysts including prospective clinical trial results and announced acquisitions.
- newswire.ca14:00
/CNW/ -- Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that it successfully completed negotiations with the pan-Canadian Pharmaceutical...
- investegate.co.uk18:15
Comprehensive details of regulatory and non regulatory announcements from FTSE 100, 250, AIM and techMARK quoted companies
Wed, 19 August 2026
1 report- manilatimes.net06:09
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
Fri, 21 August 2026
2 reports- selectscience.net04:30
Harbour BioMed’s HBM7004 IND wins NMPA approval for advanced solid tumors, highlighting novel B7H4xCD3 immunotherapy. Read expert insights on SelectScience.
- finanznachrichten.de13:06
U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO)PharmAla has exercised its
Mon, 24 August 2026
1 report- prnewswire.com07:01
/PRNewswire/ -- ImmunoForge (Co-CEOs Sung-Min Ahn and Ki-Ho Chang), a biotech venture specializing in the development of therapeutics for rare diseases,...
Tue, 25 August 2026
7 reports- mondaq.com00:00
FDA-related uncertainty is fundamentally reshaping transaction strategy across the life sciences sector, introducing new complexity into deal structuring and valuation despite strong M&A activity. Shifting regulatory signals, leadership changes, and evolving policy priorities are forcing acquirors to adapt through more creative structuring and strategic, targeted acquisitions.
- manilatimes.net02:40
NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs” or the 'Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to the expansion phase based on encouraging efficacy signals and a favorable safety profile.
- South China Morning Post05:00edited after publishing
previously
As global drug giants grow cautious, can Chinese biotech keep cashing in on out-licensing?Record-breaking cross-border deals helped make some formerly loss-making Chinese biotech companies profitable in the first half of the year, but multinational drugmakers are now signalling plans to tighten deal budgets. Analysts said deals with global partners had overtaken initial public offerings and pre-IPO fundraising as the main funding option for cash-starved Chinese biotech firms wanting to advance the discovery, clinical development and regulatory approval of new drugs. Yet questions...
- manilatimes.net10:03
$400,000 program extends AST-004 into another major CNS indication and reinforces the breadth of its cerebroprotective potential
- chinamoneynetwork.com14:15
Sinobioway Pharmaceutical Group (Hong Kong Stock Exchange Code: 01801), a leading biopharmaceutical company focusing on innovative drugs in the fields of oncology, metabolism, cardiovascular, autoimmune, and ophthalmology diseases, announced its 2026 mid-year performance and the company's 2030 strategic vision. Dr. Yu Dechao, Founder, Chairman, and CEO of Sinobioway Pharmaceutical Group, stated that the company had completed two key transformations in the past fifteen years. The company...
- leaderpost.com14:43
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+
- insidermonkey.com18:28
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) signed an all-stock merger agreement with Slate Medicines that would turn the public company into a migraine-focused biotechnology business.
Wed, 26 August 2026
1 report- rttnews.com14:06
Mabion (MAB) and Oddifact received an FDA Type B pre-IND meeting for RTX-NP (MabionCD20) in immune thrombocytopenia (ITP). The meeting will support regulatory alignment on the program's development strategy and potential BLA submission.
Thu, 27 August 2026
2 reports- South China Morning Post02:07edited after publishing
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase three trial for biliary tract cancer. The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharmaceutical industry increasingly looks to compete on the global stage. The Chinese trial tested ivonescimab and...
- miragenews.com12:00
This prospective, multicenter phase II study was conducted across 12 medical institutions in China and registered at ClinicalTrials.gov (NCT05536154
Fri, 28 August 2026
3 reports- insidermonkey.com00:11
The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)
- rttnews.com05:44
Samsung Biologics Co.,Ltd. (207940.KS), a biopharmaceutical contract development and manufacturing organization (CDMO), announced a rights offering expected to raise about KRW 3 trillion to fund its expansion across manufacturing capacity, portfolio and geographic reach.
- clinicalleader.com14:00
Recruiting for rare acute diseases is challenging. Discover how this organization used rapid site activation and investigator engagement to speed enrollment in a Phase III Anti-GBM trial.
Sat, 29 August 2026
4 reports- insidermonkey.com02:28
CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients.
- newswise.com06:45
Phase 2 TRANQUILITY trial results presented by Mount Sinai investigator support further evaluation of pacibekitug in cardiovascular disease
- blayneychronicle.com.au17:30
The federal government has expanded the range of cancers a drug will be subsidised to treat as part...
1 reprint
- cessnockadvertiser.com.au29 Aug, 17:30their copy
- themarketsdaily.com20:20
Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT – Get Free Report) was the target of a significant increase in short interest during the month of August. As of August 14th, there was short interest totaling 26,155 shares, an increase of 148.4% from the July 30th total of 10,531 shares. Currently, 2.9% of the shares of the […]
Tue, 1 September 2026
7 reports- healio.com00:00
The FDA has approved the first treatment for essential thrombocythemia in nearly 30 years, according to a PharmaEssentia press release. Ropeginterferon alfa-2b-njft (Besremi, PharmaEssentia Corporation) received approval for adults no matter their genotype or disease status.
- El País (Spain)03:30
El intento de fusión entre AstraZeneca y Bristol Myers evidencia un cambio de ciclo en el sector
- standard-freeholder.com05:04
GHENT, Belgium & TOKYO -- H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II
- finanznachrichten.de09:06
New license agreement enables an integrated workflow combining antibody labeling, human-relevant 3D testing and quantitative imaging for antibody-based therapeutics Debiopharm (Debiopharm Research
- finanznachrichten.de15:34
BEDMINSTER, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to JBS-003 (18F-fluoromisonidazole
- prnewswire.com20:05
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- prnewswire.com20:05
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
Wed, 2 September 2026
3 reports- sina.com.hk00:00
Collaboration will use NewBiologix’s Xcell™ platform to establish a scalable manufacturing foundat…
- manilatimes.net03:00
**media[1199190]**The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients.Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement and broaden access to 68Ga-PSMA-PET imaging across a significantly larger patient population.BiPASS is designed to evaluate the diagnostic performance of 68Ga-PSMA-11 PET combined with MRI for...
- Anadolu Agency (AA)22:06
COVID-19 treatment Mprosevir took just 3.5 years from discovery of drug candidate to completion of clinical trials
Thu, 3 September 2026
4 reports- finanzen.ch04:30
(RTTNews) - Today, we bring you a list of six stocks to watch in the coming days and months. Each company has potentially market-moving catalysts ...
- manilatimes.net16:22
Presentations will highlight the clinical utility and long-term commercial opportunity of GENFIT’s proprietary NIS platform, a non-invasive diagnostic technology for MASH Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 3, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it will host a virtual key opinion leader (KOL) event on...
- jcnnewswire.com17:45
- clinicalleader.com17:45
09/03/26 Clinical Leader Newsletter
Fri, 4 September 2026
12 reports- bioworld.com00:15
GSK plc is moving further into antibody-drug conjugates, taking ex-China rights to Hutchmed Ltd.’s HMPL-A830 in a deal worth up to $1.295 billion, plus royalties. Of that, GSK is paying $110 million up front for the preclinical asset, which features a dual mode of action, linking an anti-epidermal growth factor receptor (EGFR) antibody to a small-molecule KRAS inhibitor payload. The product is designed to deliver the inhibitor directly to EGFR-expressing tumors and to simultaneously block EGFR...
- finanznachrichten.de01:34
-4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with
- manilatimes.net11:52
Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments where conventional cables and plug-in infrastructure cannot operate.
- manilatimes.net12:12
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ('RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin)...
- manilatimes.net12:13
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET.
- manilatimes.net12:13
DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common...
- manilatimes.net12:13
SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
- manilatimes.net12:13
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:
- manilatimes.net12:13
AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ('Rein') (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.
- clinicalleader.com13:00
09/04/26 Clinical Leader Newsletter
- finanznachrichten.de14:38
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus
- miragenews.com19:15
The World Health Organization (WHO) has issued its first-ever invitation for expression of interest for manufacturers of childhood cancer medicines